Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid Publication Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid CertaraFebruary 10, 2014
Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers Publication Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers CertaraOctober 10, 2013
Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate Publication Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate CertaraOctober 1, 2013
Pharmacokinetics of a Three-way Drug Interaction Between Danoprevir, Ritonavir, and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin Publication Pharmacokinetics of a Three-way Drug Interaction Between Danoprevir, Ritonavir, and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin CertaraSeptember 1, 2013
Pharmacokinetic-pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies Publication Pharmacokinetic-pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies CertaraAugust 1, 2013
A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail Publication A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail CertaraJuly 20, 2013
Pharmacokinetic and Pharmacodynamic Modeling to Determine the Human Dose of ST-246(R) to Protect Against Smallpox Publication Pharmacokinetic and Pharmacodynamic Modeling to Determine the Human Dose of ST-246(R) to Protect Against Smallpox Although smallpox has been eradicated, the United States government considers it a "material threat" and…CertaraMarch 1, 2013
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model Publication Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model The pharmacokinetics (PK) of efavirenz (EFV) is characterized by marked inter-patient variability that correlates with…CertaraOctober 1, 2012
Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients Publication Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients TBR-652 is a novel CCR5 antagonist with potent in vitro anti-HIV activity. The objective of…CertaraApril 12, 2011
Combining Drug-disease and Economic Modeling to Inform Drug Development Decisions Publication Combining Drug-disease and Economic Modeling to Inform Drug Development Decisions Drug-disease models and clinical trial simulations are increasingly being used to support trial design and…CertaraNovember 1, 2001